Zobrazeno 1 - 10
of 24
pro vyhledávání: ''
Publikováno v:
International Journal of Gynecologic Cancer. 28:713-720
ObjectiveThis study aimed to investigate the role of neoadjuvant bleomycin, etoposide, and cisplatin (BEP) regimen in patients with extensively advanced yolk sac tumors (YSTs).MethodsBetween July 1982 and December 2015, a total of 58 patients with YS
Publikováno v:
International Journal of Gynecologic Cancer. 30:726-727
Up until the last Ovarian Cancer Consensus Conference in 2015,[1][1] standard treatment for advanced-stage ovarian cancer was established to be intravenous 3-weekly carboplatin and paclitaxel, with the addition of maintenance bevacizumab considered a
Autor:
Laura Woodhouse, Aiste McCormick, P. Cross, Richard J. Edmondson, Rachel O'Donnell, Angelika Kaufmann, Nicola J. Curtin
Publikováno v:
International Journal of Gynecologic Cancer. 26:1004-1011
IntroductionEpithelial ovarian cancer is recognized to be heterogeneous but is currently treated with a single treatment strategy. Successful patient stratification of emerging chemotherapy agents is dependent upon the availability of reliable biomar
Autor:
Véronique D'Hondt, Damien Dresse, Lionel Cordier, Frédéric Goffin, Joseph Kerger, Chantal Leroy, L. Roca, Isabelle Veys, Gabriel Liberale, Hélène de Forges
Publikováno v:
International Journal of Gynecologic Cancer. 26:912-917
ObjectivesWe conducted a phase 2 trial to assess the feasibility of interval cytoreductive surgery (CS) and hyperthermic intraperitoneal chemotherapy (HIPEC) with cisplatin in patients with stage III and IV pleural ovarian carcinoma in first-line tre
Autor:
Miriam D. Post, Monique A. Spillman, Lubna Qamar, Bradley R. Corr, Rachel B. Rosen, Kian Behbakht, Carol A. Sartorius, Jessica Finlay-Schultz
Publikováno v:
International Journal of Gynecologic Cancer. 25:1565-1573
ObjectiveCytokeratin 5 (CK5) is an epithelial cell marker implicated in stem and progenitor cell activity in glandular reproductive tissues and endocrine and chemotherapy resistance in estrogen receptor (ER)+breast cancer. The goal of this study was
Publikováno v:
International Journal of Gynecologic Cancer. 24:1381-1388
ObjectivePlatinum-based chemotherapy is the standard treatment in advanced ovarian cancer, but most patients will relapse with drug-resistant disease. MicroRNAs have been demonstrated to function in chemoresistance in cancers. In this study, we focus
Publikováno v:
International Journal of Gynecologic Cancer. 22:1220-1225
ObjectiveRetrospectively, to assess the toxicity of delivering postoperative extended-field intensity-modulated radiotherapy (EF-IMRT) and concurrent cisplatin chemotherapy for patients with cervical cancer with a pathologically confirmed positive co
Publikováno v:
International Journal of Gynecologic Cancer. 22:1118-1124
PurposeTo investigate the role of Beclin 1 expression on the cisplatin-induced apoptosis in cervical cancer CaSki cells and to explore the potential mechanism underlying this effect.Materials and MethodsAfter overexpression or partial silencing of Be
Publikováno v:
International Journal of Gynecologic Cancer. 21:1540-1546
ObjectivesThe aim of this study was to investigate the combined effects of a novel survivin promoter-based conditionally replicating adenovirus (CRAd-S.RGD) pluscis-diamminedichloroplatinum (cisplatin, CDDP) in ovarian cancer in vitro and in vivo.Met
Publikováno v:
International Journal of Gynecologic Cancer. 19:460-465
Carboplatin is one of the most commonly used and well-tolerated agents for gynecologic malignancies. The rate of hypersensitivity reactions (HSRs) in the overall population of patients receiving carboplatin has been reported to increase after multipl